Logo

Color: Jill Hagenkord

Aug 22, 2019

Jill Hagenkord is no longer chief medical officer of genetic testing firm Color, and has started a new consulting company, called MDisrupt. Hagenkord previously held executive positions at Invitae, 23andMe, and Complete Genomics. She co-founded MDisrupt with another 23andMe alum, Ruby Gadelrab, who is serving as CEO. The start-up describes itself as a "medical diligence company" that aims to help companies speed innovative products to market by "assessing a product's clinical and commercial viability in a healthcare setting."

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.